Drug Company CEOs Under Pressure
Main Category: Pharma Industry / Biotech IndustryAlso Included In: Health Insurance / Medical Insurance
Article Date: 04 Feb 2010 - 5:00 PDT
| Patient / Public: | ![]() |
1.5 (2 votes) |
| Healthcare Prof: | ![]() |
5 (1 votes) |
News outlets feature profiles and opinions of the CEOs of some of the largest American drug manufacturers.
Dow Jones Newswires/The Wall Street Journal on Severin Schwan, chief executive of Swiss pharmaceutical company Roche Holding AG: "'It is difficult to gauge the impact of the planned U.S. healthcare reform on the pharmaceutical industry,' Schwan told reporters at a media conference to detail 2009 earnings. 'On the one hand, more U.S. citizens will be getting access to healthcare, which is positive. At the same time, pressure on drug prices will certainly increase,' he added." The wire service adds that he also said "decisions on generic biosimilars will be key" (Greil, 2/3).
The Seattle Times on GlaxoSmithKline PLC CEO Andrew Witty: "[He] has been remaking the company from a pure pharmaceutical business to a diverse healthcare conglomerate, a strategy most rivals now are pursuing. ... Like rivals, it is losing sales to generic competition and reducing staff in Western countries. Witty is pushing to sell more products in fast-growing 'emerging markets' such as Brazil, Russia, India and China. But Witty also is increasing efforts to bring medicines for tropical diseases to the poorest countries, at minimum profit" (Johnson, 2/2).
In a separate article, Dow Jones Newswires/The Wall Street Journal reports on a high and "generational" turnover among pharmaceutical CEOs. "The new leaders are taking over an industry under pressure. The past decade has brought heightened scrutiny of drug safety, government probes of sales and marketing practices, and greater pricing pressure from drug-benefit plans and generic competitors. Drug makers feel compelled to control costs and do more to get results from the billions of dollars they pour into their research labs" (Loftus, 2/2).
This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org.
© Henry J. Kaiser Family Foundation. All rights reserved.
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/178158.php>
APA
http://www.medicalnewstoday.com/releases/178158.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




